|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...29303132333435363738394041» |
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Metastases: Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 19, 2012
P2, N=27, Completed, Sponsor: National Cancer Institute (NCI)
N=35 --> 27
- Zolinza (vorinostat) / Merck (MSD)
Trial completion, Metastases: Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 19, 2012
P2, N=27, Completed, Sponsor: National Cancer Institute (NCI)
N=35 --> 27 Active, not recruiting --> Completed
- || dalfampridine / Generic mfg.
New P2/3 trial: Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients? (clinicaltrials.gov) - Aug 15, 2012
P2/3, N=58, Not yet recruiting, Sponsor: London Health Sciences Centre
- || amphetamine/dextroamphetamine ER / Generic mfg.
New P2/3 trial: Adderall XR and Processing Speed in Multiple Sclerosis (MS) (clinicaltrials.gov) - Aug 15, 2012
P2/3, N=60, Not yet recruiting, Sponsor: London Health Sciences Centre
- ||| Betaseron (IFN-β-1b) / Bayer
Trial completion, P4 data: Betaferon® Regulatory Post-Marketing Surveillance (clinicaltrials.gov) - Aug 15, 2012
P=N/A, N=355, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Recruiting --> Completed
- ||| Biomarker, Trial completion: EMR 200077- 500: To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple Sclerosis (clinicaltrials.gov) - Aug 15, 2012
P=N/A, N=301, Completed, Sponsor: Merck KGaA
Recruiting --> Completed Active, not recruiting --> Completed
- New P1 trial, IO biomarker: Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health (clinicaltrials.gov) - Aug 15, 2012
P1, N=60, Recruiting, Sponsor: Johns Hopkins University
- methylprednisolone sodium succinate / Generic mfg.
Enrollment open: Optic Neuritis Recovery After Oral or IV Corticosteroids (clinicaltrials.gov) - Aug 12, 2012
P2/3, N=46, Recruiting, Sponsor: London Health Sciences Centre
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Clinical: Effectiveness of Web-based Treatment for Depression in Patients With Neurologic Disorders (clinicaltrials.gov) - Aug 9, 2012
P=N/A, N=200, Recruiting, Sponsor: Universitätsklinikum Hamburg-Eppendorf
- ||| Zinbryta (daclizumab) / Biogen, AbbVie
Enrollment closed, Monotherapy: SELECTED: Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Aug 8, 2012
P2, N=600, Active, not recruiting, Sponsor: Biogen Idec
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Rebif (human IFN-β-1a) / EMD Serono
Trial completion: Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis (clinicaltrials.gov) - Aug 7, 2012
P=N/A, N=60, Completed, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Tysabri (natalizumab) / Biogen, Royalty
New P4 trial: CogMS: Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients (clinicaltrials.gov) - Aug 5, 2012
P4, N=60, Active, not recruiting, Sponsor: Clinique Neuro-Outaouais
- Avonex (recombinant IFN-β-1a) / Biogen
Trial termination: CHAMPIONS CONT: Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance (clinicaltrials.gov) - Aug 1, 2012
P=N/A, N=383, Terminated, Sponsor: Biogen Idec
Active, not recruiting --> Completed Recruiting --> Terminated; low enrollment
- ||||| Avonex (recombinant IFN-β-1a) / Biogen, Zinbryta (daclizumab) / Biogen, AbbVie
Enrollment closed, Monotherapy: Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Aug 1, 2012
P3, N=1800, Active, not recruiting, Sponsor: Biogen Idec
Recruiting --> Terminated; low enrollment Recruiting --> Active, not recruiting
- | dalfampridine / Generic mfg.
New P4 trial: FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra (clinicaltrials.gov) - Jul 31, 2012
P4, N=125, Active, not recruiting, Sponsor: University of Southern Denmark
- | dalfampridine / Generic mfg.
Trial completion: An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - Jul 29, 2012
P2, N=20, Completed, Sponsor: Acorda Therapeutics
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial initiation date: Mechanical Stress Effects on the Cardiovascular Adaptations of Peripheral Arterial Calcifications Among Athletes (clinicaltrials.gov) - Jul 25, 2012
P=N/A, N=90, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Active, not recruiting --> Completed Initiation date: Jun 2012 --> Sep 2012
- | pregabalin / Generic mfg., paroxetine / Generic mfg.
Trial completion: Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic Pain (clinicaltrials.gov) - Jul 25, 2012
P3, N=75, Completed, Sponsor: University of Manitoba
Initiation date: Jun 2012 --> Sep 2012 Recruiting --> Completed
- | Cesamet (nabilone) / Bausch Health, Viatris
Trial completion: Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis (clinicaltrials.gov) - Jul 25, 2012
P4, N=50, Completed, Sponsor: University of Manitoba
Recruiting --> Completed Recruiting --> Completed
- | fipaxalparant (AMG 670) / Amgen
New P2 trial: Proof of Biological Activity of SAR100842 in Systemic Sclerosis (clinicaltrials.gov) - Jul 24, 2012
P2, N=30, Active, not recruiting, Sponsor: Sanofi
- ||||| selurampanel (BGG492) / Novartis
New P2 trial: Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis (clinicaltrials.gov) - Jul 23, 2012
P2, N=145, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Enrollment closed: A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients (clinicaltrials.gov) - Jul 22, 2012
P1/2, N=25, Active, not recruiting, Sponsor: Department of Veterans Affairs
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Clinical: Impact of Early Non Invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Patients (clinicaltrials.gov) - Jul 15, 2012
P=N/A, N=72, Recruiting, Sponsor: Hospital Universitari de Bellvitge
- || Enrollment closed: Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI) (clinicaltrials.gov) - Jul 13, 2012
P=N/A, N=60, Active, not recruiting, Sponsor: Genetic Disease Investigators
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| New P4 trial: Sacroiliac Joint Fusion With iFuse Implant System (SIFI) (clinicaltrials.gov) - Jul 11, 2012
P4, N=250, Active, not recruiting, Sponsor: SI-BONE, Inc.
- ||| Trial completion: JEMS: JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS) (clinicaltrials.gov) - Jul 11, 2012
P=N/A, N=2000, Completed, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting Recruiting --> Completed
- New P1 trial: hNSCALS: Human Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Jul 11, 2012
P1, N=18, Recruiting, Sponsor: Azienda Ospedaliera Santa Maria, Terni, Italy
- Campath (alemtuzumab) / Sanofi
New P1/2 trial: Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis (clinicaltrials.gov) - Jul 10, 2012
P1/2, N=6, Recruiting, Sponsor: Children's Hospital Los Angeles
- zoledronic acid / Generic mfg.
Trial termination: EXALT: Zoledronic Acid in MS-patients With Osteoporosis (clinicaltrials.gov) - Jul 8, 2012
P3, N=29, Terminated, Sponsor: Novartis
Recruiting --> Completed Active, not recruiting --> Terminated
- | everolimus / Generic mfg.
Enrollment change: Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) (clinicaltrials.gov) - Jul 8, 2012
P1/2, N=20, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Active, not recruiting --> Terminated N=10 --> 20
- Trial termination: Immunoadsorption in Patients With Severe Systemic Sclerosis (clinicaltrials.gov) - Jul 8, 2012
P=N/A, N=1, Terminated, Sponsor: GWT-TUD GmbH
N=10 --> 20 Recruiting --> Terminated; inadequately recruitment rate, funding is not secured
- ||| dalfampridine / Generic mfg.
Enrollment closed, HEOR: ENABLE: Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis (clinicaltrials.gov) - Jul 4, 2012
P4, N=800, Active, not recruiting, Sponsor: Biogen Idec
Recruiting --> Terminated; inadequately recruitment rate, funding is not secured Recruiting --> Active, not recruiting
- |||| Betaseron (IFN-β-1b) / Bayer
Trial completion: Betaseron Pregnancy Registry (clinicaltrials.gov) - Jul 1, 2012
P4, N=113, Completed, Sponsor: INC Research
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment open: Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS (clinicaltrials.gov) - Jun 28, 2012
P=N/A, N=50, Recruiting, Sponsor: University of Southern California
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| dalfampridine / Generic mfg.
Enrollment open: Fampridine Pregnancy Exposure Registry (clinicaltrials.gov) - Jun 27, 2012
P=N/A, N=375, Recruiting, Sponsor: Biogen Idec
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment change: Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma (clinicaltrials.gov) - Jun 25, 2012
P1, N=14, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting N=18 --> 14
- | Trial completion: Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma (clinicaltrials.gov) - Jun 25, 2012
P1, N=14, Completed, Sponsor: M.D. Anderson Cancer Center
N=18 --> 14 Active, not recruiting --> Completed
- |||| tabalumab (LY2127399) / Eli Lilly
Trial completion: A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Jun 21, 2012
P2, N=245, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Enrollment change: Digital Ulceration (clinicaltrials.gov) - Jun 20, 2012
P=N/A, N=630, Completed, Sponsor: Actelion
Active, not recruiting --> Completed N=500 --> 630
- Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe
Enrollment open: Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Jun 17, 2012
P1, N=28, Recruiting, Sponsor: MedImmune LLC
N=500 --> 630 Not yet recruiting --> Recruiting
- New P4 trial: ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon (clinicaltrials.gov) - Jun 14, 2012
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
- zoledronic acid / Generic mfg.
Enrollment change: EXALT: Zoledronic Acid in MS-patients With Osteoporosis (clinicaltrials.gov) - Jun 13, 2012
P3, N=29, Terminated, Sponsor: Novartis
Not yet recruiting --> Recruiting N=200 --> 29
- doxycycline / Generic mfg.
Enrollment closed: Doxycycline In Lymphangioleiomyomatosis (LAM) (clinicaltrials.gov) - Jun 13, 2012
P4, N=40, Active, not recruiting, Sponsor: University of Nottingham
N=200 --> 29 Recruiting --> Active, not recruiting
- | Rebif (human IFN-β-1a) / EMD Serono
Trial completion: The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment (clinicaltrials.gov) - Jun 13, 2012
P=N/A, N=20, Completed, Sponsor: University of South Florida
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- Enrollment change: A Randomized Exercise Trial for Wheelchair Users (clinicaltrials.gov) - Jun 12, 2012
P=N/A, N=135, Completed, Sponsor: University of Kansas
Enrolling by invitation --> Completed N=180 --> 135
- Trial completion: A Randomized Exercise Trial for Wheelchair Users (clinicaltrials.gov) - Jun 12, 2012
P=N/A, N=135, Completed, Sponsor: University of Kansas
N=180 --> 135 Active, not recruiting --> Completed
- Trial withdrawal, IO biomarker: WIRMS-1: Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis. (clinicaltrials.gov) - Jun 12, 2012
P2, N=0, Withdrawn, Sponsor: University of Nottingham
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change, IO biomarker: WIRMS-1: Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis. (clinicaltrials.gov) - Jun 12, 2012
P2, N=0, Withdrawn, Sponsor: University of Nottingham
Not yet recruiting --> Withdrawn N=30 --> 0
- Enrollment change: Investigation of Coronary and Pulmonary Circulatory Parameters in Systemic Sclerosis (clinicaltrials.gov) - Jun 11, 2012
P=N/A, N=120, Completed, Sponsor: University of Pecs
N=30 --> 0 N=150 --> 120
- Trial completion: Investigation of Coronary and Pulmonary Circulatory Parameters in Systemic Sclerosis (clinicaltrials.gov) - Jun 11, 2012
P=N/A, N=120, Completed, Sponsor: University of Pecs
N=150 --> 120 Recruiting --> Completed